Batu Biologics Recruits Vice President of Precision Oncology

17 October 2018

Batu Biologics Recruits Dr. Vijay Mahant as the Vice President of Precision Oncology to Oversee the Personalization of ValloVax Immunogenicity Dr. Mahant to assist with the development of screening criteria to identify patients who are most likely to receive clinical benefit from the ValloVax immunotherapy Today, Batu Biologics announced the recruitment of Dr. Vijay Mahant … Continue reading "Batu Biologics Recruits Vice President of Precision Oncology"....

Read Full Article About Businesswire.com

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog

24 September 2018

Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog Clinical Stage Immuno-Oncology Company Releases Media Platform to Provide Background Information on Lead Technology Today, Batu Biologics announced the release of the Starve The Tumor Video Blog, a series of informational videos and articles designed to provide background information on our lead therapeutic … Continue reading "Batu Biologics Announces the Release of the Starve The Tumor Immunotherapy Blog"....

Read Full Article About Businesswire.com

Batu Biologics Identifies Gene Types Associated with Response to ValloVax

20 August 2018

Batu Biologics Identifies Gene Types Associated with Response to ValloVax Preliminary Evaluation of Over 100 Patients Treated with Cancer Blood Vessel Targeting Immunotherapy Reveals Gene Association with Clinical Response Batu Biologics announced today filing of a patent covering methods of matching cancer patients with experimental drugs under the new Right to Try Law. The recently … Continue reading "Batu Biologics Identifies Gene Types Associated with Response to ValloVax"....

Read Full Article About Businesswire.com

Batu Biologics files Right to Try Patent

26 July 2018

Batu Biologics Files Patent on Patient Selection for Right to Try Law Clinical Stage Immunotherapy Company Creates System of Selecting Patients for Optimized Outcome under President Donald Trump’s Right to Try Law Batu Biologics announced today filing of a patent covering methods of matching cancer patients with experimental drugs under the new Right to Try … Continue reading "Batu Biologics files Right to Try Patent"....

Read Full Article About Businesswire.com

Batu Biologics Recruits Nobel Prize Winner Bruce Beutler

12 June 2018

Nobel Prize Winning Immunologist Joins Batu Biologics in Quest to “Starve the Tumor” Clinical Stage Immuno-Oncology Company Recruits Pioneer of Innate Immunity to Scientific Advisory Board Batu Biologics announced today the appointment of Nobel Prize winner Dr. Bruce Beutler to the Company’s Scientific Advisory Board. Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Batu Biologics Releases Shareholder Letter

31 May 2018

Company discusses the clinical progress of the ValloVax Therapeutic Vaccine at the CHIPSA Hospital Samuel C. Wagner, President and CEO of Batu Biologics, has issued the following letter to the shareholders of the Company, providing a comprehensive update on the clinical progress of the ValloVax immune therapy: Read the full article at businesswire.com....

Read Full Article About Businesswire.com

Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board

24 March 2018

Pioneer of Tumor Immunotherapy Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board Former President of the Society for Immunotherapy of Cancer to Assist Company in Advancement of its Anti-Angiogenesis Immunotherapy Product ValloVax Batu Biologics, committed to advancement of its clinical stage cancer immunotherapeutic, ValloVax™, announced today the appointment of Dr. Francesco … Continue reading "Dr. Francesco Marincola Appointed as Chairman of Batu Biologics Clinical Advisory Board"....

Read Full Article About Businesswire.com

Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium

16 March 2018

Batu Biologics Chief Executive Officer Samuel Wagner to Moderate Congressional Immunotherapy Symposium Congressional Candidate to Hear Concerns of Industry Leaders in Health Care Innovations Batu Biologics, a clinical stage immunotherapy company, announced today its Chief Executive Officer, Samuel Wagner, was chosen to moderate an internationally renowned panel of biotechnology companies focusing on immunotherapy. Read the … Continue reading "Batu Biologics CEO to Moderate Congressional Immunotherapy Symposium"....

Read Full Article About Businesswire.com

Batu Biologics CEO Selected for Lyfebulb Oncology Award

2 March 2018

Batu Biologics CEO Selected as Finalist for Lyfebulb-Helsinn Innovation Summit and Award For Oncology Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, today announced the names of … Continue reading "Batu Biologics CEO Selected for Lyfebulb Oncology Award"....

Read Full Article About Businesswire.com

Batu Biologics Raises $1.3 Million in Equity Crowdfunding

25 December 2017

Batu Biologics Successfully Completes $1.3 Million #Starvethetumor Equity Crowdfunding Campaign Company Intends to Aggressively Pursue Clinical Development of Angiogenesis Targeting Immunotherapy Product ValloVax Batu Biologics, an immuno-oncology Company dedicated to the development of its clinical stage tumor-angiogenesis targeting immunotherapy, ValloVax™, announced today the successful closure of a regulation 506(c) equity crowdfunding offering bringing in $1.3 … Continue reading "Batu Biologics Raises $1.3 Million in Equity Crowdfunding"....

Read Full Article About Businesswire.com
1 2 3 6